title: Role of factor H binding protein in Neisseria meningitidis virulence and its potential as a vaccine candidate to broadly protect against meningococcal disease.
abstract: Neisseria meningitidis is a Gram-negative microorganism that exists exclusively in humans and can cause devastating invasive disease. Although capsular polysaccharide-based vaccines against serogroups A, C, Y, and W135 are widely available, the pathway to a broadly protective vaccine against serogroup B has been more complex. The last 11 years has seen the discovery and development of the N. meningitidis serogroup B (MnB) outer membrane protein factor H binding protein (fHBP) as a vaccine component. Since the initial discovery of fHBP, a tremendous amount of work has accumulated on the diversity, structure, and regulation of this important protein. fHBP has proved to be a virulence factor for N. meningitidis and a target for functional bactericidal antibodies. fHBP is critical for survival of meningococci in the human host, as it is responsible for the primary interaction with human factor H (fH). Binding of hfH by the meningococcus serves to downregulate the host alternative complement pathway and helps the organism evade host innate immunity. Preclinical studies have shown that an fHBP-based vaccine can elicit serum bactericidal antibodies capable of killing MnB, and the vaccine has shown very encouraging results in human clinical trials. This report reviews our current knowledge of fHBP. In particular, we discuss the recent advances in our understanding of fHBP, its importance to N. meningitidis, and its potential role as a vaccine for preventing MnB disease.
authors.affiliation: Pfizer Vaccine Research, Pearl River, New York, USA.
authors.forename: Lisa K
authors.initials: LK
authors.lastname: McNeil
authors.forename: Robert J
authors.initials: RJ
authors.lastname: Zagursky
authors.forename: Shuo L
authors.initials: SL
authors.lastname: Lin
authors.forename: Ellen
authors.initials: E
authors.lastname: Murphy
authors.forename: Gary W
authors.initials: GW
authors.lastname: Zlotnick
authors.forename: Susan K
authors.initials: SK
authors.lastname: Hoiseth
authors.forename: Kathrin U
authors.initials: KU
authors.lastname: Jansen
authors.forename: Annaliesa S
authors.initials: AS
authors.lastname: Anderson
mesh_terms: D000942:Antigens, Bacterial / Q000737:chemistry / Q000276:immunology / Q000378:metabolism*; D001426:Bacterial Proteins / Q000737:chemistry / Q000276:immunology / Q000378:metabolism*; D006801:Humans; D008589:Meningococcal Infections / Q000276:immunology / Q000517:prevention & control*; D022401:Meningococcal Vaccines / Q000276:immunology* / Q000378:metabolism; D009345:Neisseria meningitidis / Q000276:immunology / Q000378:metabolism* / Q000472:pathogenicity; D011487:Protein Conformation; D014774:Virulence / Q000276:immunology
chemical_list: D000942:Antigens, Bacterial; D001426:Bacterial Proteins; D022401:Meningococcal Vaccines; C484699:factor H-binding protein, Neisseria meningitidis